MYC and metastatic neoplasm: Of clinical relevance, Qiu, Boufaied and colleagues revealed that a low AR and high MYC transcriptional signature in patient tumors was associated with shorter time to biochemical recurrence, increased risk of metastatic disease, and higher likelihood of developing resistance to ARSI treatment (65).